ABSTRACT
Objective: To investigate and evaluate the effect of components in Biqi Capsulae prescription compatibility on activities of cytochrome P450 (CYP450) in vivo. Methods: A new "Cocktail" one point method has been established, including five probes of Phenacetin, Tolbutamide, mephenytoin, Dextromethorphan, and midazolam. An LC-MS/MS analytical method has been established to determine the above five probes and their corresponding metabolites to analyze and evaluate the potential in vivo induction and (or) inhibition of components from Biqi Capsulae on the above five CYP450 in rats. Results: Biqi Capsulae prescription has compatibility based on CYP450. Compared with blank group, groups of "principal + assistant", "principal + mediator", "principal + assistant + complement", "principal + assistant + mediator", "principal + complement + mediator", and whole Biqi Capsulae could significantly induce the activity of CYP1A2. Moreover, groups of "principal + assistant", "principal + assistant + complement", "principal + assistant + mediator", and whole Biqi Capsulae could significantly induce the activity of CYP2C9. Conclusion: Biqi Capsulae prescription has significant compatibility based on CYP450. These results provide the important information and establish good foundation for further investigation on scientificalness and safety of Biqi Capsulae prescription compatibility.